Conference Coverage

Long-acting all-injectable HIV therapy successful in phase 2b

Publish date: August 28, 2016

 

AT AIDS 2016

References

His study was funded by the Bill and Melinda Gates Foundation.

Dr. Margolis is an employee of Viiv Healthcare, the LATTE-2 study sponsor.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Extreme alcohol use worsens HIV disease
MDedge Infectious Disease
PCR assay quicker but less sensitive at penicilliosis diagnosis
MDedge Infectious Disease
Cancer trends shifting in HIV-positive patients
MDedge Infectious Disease
Anal cancer in HIV-infected patients: to screen or not?
MDedge Infectious Disease
Better use of lab testing tools needed to beat HIV/AIDS
MDedge Infectious Disease
HIV research update: Early August 2016
MDedge Infectious Disease
Integrated PrEP and ART prevents HIV transmission in couples
MDedge Infectious Disease
Ombitasvir/paritaprevir-based HCV regimens perform well in HIV coinfection
MDedge Infectious Disease
With HIV PrEP, benefits outweigh resistance risk
MDedge Infectious Disease
Major depressive disorder increases acute MI risk in HIV
MDedge Infectious Disease